FEDERAL MARITIME COMMISSION

Ocean Transportation Intermediary License Reissuances

Notice is hereby given that the following Ocean Transportation

Intermediary licenses have been reissued by the Federal Maritime Commission pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. Chapter 409) and the regulations of the Commission pertaining to the licensing of Ocean Transportation Intermediaries, 46 CFR Part 515.

License No.	Name/address	Date reissued
001593F 013172N	Robertson Forwarding Co., Inc., 4469 NW 97th Ave., Miami, FL 33178 Yung Hoon Kim, dba Conex International, 20695 South Western Ave., Suite 136, Torrance, CA 90501.	

Name: Cargonline (USA) Inc.

Sandra L. Kusumoto,

Director, Bureau of Certification and Licensing. [FR Doc. E9-13639 Filed 6-9-09; 8:45 am] BILLING CODE 6730-01-P

FEDERAL MARITIME COMMISSION

Ocean Transportation Intermediary License Revocations

The Federal Maritime Commission hereby gives notice that the following Ocean Transportation Intermediary licenses have been revoked pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. Chapter 409) and the regulations of the Commission pertaining to the licensing of Ocean Transportation Intermediaries, 46 CFR Part 515, effective on the corresponding date shown below:

License Number: 000692F. Name: A. R. Savage & Son, Inc. Address: 701 Harbour Post Dr.,

Tampa, FL 33602. Date Revoked: May 27, 2009. Reason: Failed to maintain a valid bond.

License Number: 017799NF.

Name: Alpha Freight & Transport International, Inc.

Address: 3508 NW 114th Ave., Ste. 205, Doral, FL 33178.

Date Revoked: May 27, 2009. Reason: Surrendered license voluntarily.

License Number: 018583NF. Name: Astron Distribution, Inc. Address: 349 NW 16th Street, Ste. 107. Belle Glade, FL 33430.

Date Revoked: May 27, 2009. Reason: Failed to maintain valid bonds.

License Number: 018878N. Name: BTL Group, Inc. Dba E-World Cargo, Inc.

Address: 7910 SO. 3500 E., Ste. B, Salt Lake, UT 84121.

Date Revoked: May 6, 2009. Reason: Surrendered license

voluntarily.

License Number: 021167N.

Address: 245 E. Main Street, Ste. 112, Alhambra, CA 91801. Date Revoked: May 21, 2009. *Reason:* Failed to maintain a valid bond. License Number: 004084F. Name: Glory Express, Inc. Address: 17420 S. Avalon Blvd., Ste. 202, Carson, CA 90746. Date Revoked: May 22, 2009. Reason: Failed to maintain a valid bond. License Number: 017911N. Name: Kasy Logistics Co., Ltd. Address: 355 S. Lemon Ave., #N, Walnut, CA 91789. Date Revoked: May 29, 2009. Reason: Surrendered license voluntarily. License Number: 016503NF. Name: Lukini Shipping Inc. Address: One Cross Island Plaza, Ste. 203d, Rosedale, NY 11422. Date Revoked: May 27, 2009. Reason: Failed to maintain valid bonds. License Number: 002145F. Name: Henry Juliusburger DBA Nautique-Worldwide. Address: 55 New Montgomery St., Ste. 514, San Francisco, CA 94105. Date Revoked: May 22, 2009. Reason: Failed to maintain a valid bond. License Number: 013797N. Name: Kenneth Bola Obatusin DBA Global Freightways (USA), Ltd. Address: 10630 Riggs Hill Rd., Bldg. R, Jessup, MD 20794. Date Revoked: May 29, 2009. Reason: Failed to maintain a valid bond License Number: 016484N. Name: Kenny International USA, Inc. DBA KTL (USĂ) International. Address: 145-18 156th Street, Rm. #1, Jamaica, NY 11434. Date Revoked: April 6, 2009. *Reason:* Surrendered license voluntarily.

License Number: 020066N. Name: Manila Forwarders Corporation.

Address: 8241 Backlick Rd., Ste. B. Lorton, VA 22079.

Date Revoked: May 29, 2009. *Reason:* Failed to maintain a valid bond.

License Number: 000334F. Name: Perryman Mojonier Company. Address: 9720 S. La Cienega Blvd.,

Inglewood, CA 90301. *Date Revoked:* May 29, 2009. Reason: Failed to maintain a valid

bond.

Sandra L. Kusumoto.

Director, Bureau of Certification and Licensing.

[FR Doc. E9-13651 Filed 6-9-09; 8:45 am] BILLING CODE P

DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

National Institute for Occupational Safety and Health: Decision To Evaluate a Petition To Designate a **Class of Employees for the Norton** Company in Worcester, MA, To Be Included in the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS). **ACTION:** Notice.

SUMMARY: HHS gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees for the Norton Company in Worcester, Massachusetts, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Norton Company. *Location:* Worcester, Massachusetts. Job Titles and/or Job Duties: All

Atomic Weapons Employer employees. Period of Employment: January 1,

1945 through December 31, 1957.

FOR FURTHER INFORMATION CONTACT:

Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513– 533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to *OCAS@CDC.GOV*.

Christine M. Branche,

Acting Director, National Institute for Occupational Safety and Health. [FR Doc. E9–13662 Filed 6–9–09; 8:45 am] BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the National Coordinator for Health Information Technology; HIT Standards Committee Meeting

ACTION: Announcement of meeting.

SUMMARY: This notice announces the second meeting of the HIT Standards Committee in accordance with the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App.).

DATES: June 23, 2009, from 9 a.m. to 12 p.m. [Eastern]

ADDRESSES: The Omni Shoreham Hotel, 2500 Calvert Street, NW., Washington, DC 20008, Diplomat Ballroom.

FOR FURTHER INFORMATION CONTACT: *http://healthit.hhs.gov.*

SUPPLEMENTARY INFORMATION: The meeting will include

presentations from the HIT Standards Committee Workgroups. The meeting is a Web-based meeting with teleconference dial-in. If you have special needs for the meeting, please contact (202) 690–7151.

Judith Sparrow,

Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology. [FR Doc. E9–13630 Filed 6–9–09; 8:45 am]

BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Investigator Registration and Financial Disclosure for Investigational Trials in Cancer Treatment (NCI)

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute, the National Cancer Institute (NIH) will publish periodic summaries to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: Investigator Registration and Financial Disclosure for Investigational Trials in Cancer Treatment (NCI). Type of Information Collection Request: Existing Collection in use without an OMB Control Number. Need and Use of Information Collection: Food and Drug Administration (FDA) regulations require sponsors to obtain information from the investigator before permitting the investigator to begin participation in investigational studies. The National

Cancer Institute (NCI), as a sponsor of investigational drug trials, has the responsibility to assure the FDA that investigators in its clinical trials program are qualified by training and experience as appropriate experts to investigate the drug. In order to fulfill these requirements, a standard Statement of Investigator (FDA Form 1572 modified), Supplemental Investigator Data Form, Financial Disclosure Form and Curriculum vitae (CV) are required. The data obtained from these forms allows the NCI to evaluate the qualifications of the investigator, identify appropriate personnel to receive shipment of investigational agent, ensure supplies are not diverted for inappropriate protocol or patient use and identify financial conflicts of interest. Comparisons are done with the intention of ensuring protocol, patient safety and drug compliance for patient and drug compliance for patient safety and protections.

Frequency of Response: Annually. Affected Public: Public sector, businesses other for-profit. Federal

agencies or employees, non-profit institutions and a very small number of private practice physicians.

Type of Respondents: Health care investigators. The annual reporting burden is limited to those physicians who choose to participate in NCI sponsored investigational trials to identify new medicinal agents to treat and relieve those patients suffering from cancer. It is estimated that the total annual burden will be 8,564 hours, and include 17,128 investigators, for this project (see Table 1).

TABLE 1-ESTIMATES OF ANNUAL BURDEN

Type of respondents	Form	Number of re- spondents	Frequency of response	Average time per response	Total hour bur- den
Investigators and Designee	Statement of Investigator Supplemental Investigator	17,128 17,128	1	0.25 (15 minutes) 0.167 (10 minutes)	4,282 2,855
Totals	Financial Disclosure	17,128 17,128	1	0.083 (5 minutes)	1,427 8,564

There is no capital, operating or maintenance costs to report.

Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information; including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Charles L. Hall, Jr., Chief, Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, Division of the Cancer Treatment and Diagnosis, and Centers, National Cancer Institute, Executive Plaza North, Room 7148, 9000 Rockville Pike, Bethesda, MD 20892 or call nontoll-free number 301–496–5725 or E-